Sugi Predict

Sugi Predict / Compounds / SCHEMBL2870839

SCHEMBL2870839

SCHEMBL2870839

CC(=O)NS(=O)(=O)CC(C)(C)NC(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 6/20 0.49
▸ CA2 P00918 6/20 0.49
▸ CA12 O43570 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ CTSS P25774 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ ACHE P22303 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ ATM Q13315 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPRB P23467 1/20 0.41
▸ ACP1 P24666 1/20 0.41
▸ AAK1 Q2M2I8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2878022 0.90 MEN1 (0.49) CA1CA2CA12CA9MEN1
SCHEMBL2873030 0.84 CA1 (0.51) CA1CA2CA12CA9MEN1
SCHEMBL2873356 0.83 CA1 (0.50) CA1CA2CA12CA9MEN1
SCHEMBL2873755 0.83 CA2 (0.57) CA1CA2CA12CA9MEN1
SCHEMBL2870594 0.83 CA1 (0.50) CA1CA2CA12CA9MEN1
SCHEMBL2873353 0.82 MEN1 (0.49) CA1CA2CA12CA9MEN1
SCHEMBL2870452 0.81 SMN1; SMN2 (0.48) CA1CA2CA12CA9MEN1
SCHEMBL2873085 0.80 MEN1 (0.47) CA1CA2CA12CA9MEN1
SCHEMBL14590977 0.78 MEN1 (0.53) CA1CA2CA12CA9MEN1
SCHEMBL8282485 0.78 MEN1 (0.58) CA1CA2CA12CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120965-B1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS INC (US) 2014-11-05 — — EP disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 — — US disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 — — US disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 — — US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 — — US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 — — US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES DCTD, DDC, DAO CA1 4664/4885CA2 4613/4885CA12 4784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.